# Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

> **NCT03075267** · PHASE1 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 96 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** PT010 (BGF MDI) 320/14.4/9.6 µg
- **DRUG:** PT010 (BGF MDI) 160/14.4/9.6 µg
- **DRUG:** PT003 (GFF MDI) 14.4/9.6 µg

## Key facts

- **NCT ID:** NCT03075267
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-17
- **Primary completion:** 2017-09-05
- **Final completion:** 2017-09-05
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2021-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03075267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03075267, "Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03075267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*